scope and safety
Renal toxicity monitoring can be the actionable renal information
The source provides monitoring and stop conditions for a urinary irrigation product rather than a clearance-based systemic dose.
What to reconcileConfirm route and patency, preserve monitoring frequency and stop criteria, and do not create an intravenous regimen.
1 source identities and dates
GlobalRPh RX List - RENACIDINGlobalRPh-hosted RX List | Source revision: Source revision date not established in selected retrieval.
Renacidin - urinary tract irrigation solution; selected renal passages, not a complete prescribing monograph.
Read this stored source Source-specific interpretation; independent clinician adjudication pending. Added: v5.2.
dated source difference
REZDIFFRA: March 2024 mirror versus July 2026 official renal evidence
The older mirror leaves severe impairment unstudied. The newer official section addresses severe impairment explicitly. This is a dated evidence difference, not two interchangeable current instructions.
What to reconcileUse the current official renal section in its full product context. Preserve each study method and do not extend a nondialysis finding to an unsupported dialysis regimen.
2 source identities and dates
GlobalRPh RX List - REZDIFFRAGlobalRPh-hosted RX List | Source revision: RX mirror prints March 2024.
Resmetirom - REZDIFFRA tablets; selected renal passages, not a complete prescribing monograph.
Read this stored source REZDIFFRA - official renal evidence recheckDailyMed / Madrigal Pharmaceuticals, Inc. | Source revision: Prescribing information revised July 2026.
REZDIFFRA - official renal evidence recheck; selected renal passages, not a complete prescribing monograph.
Read this stored source Source-specific interpretation; independent clinician adjudication pending. Added: v5.2.
scope and safety
PK observations do not establish a lower-function regimen
The selected source leaves severe impairment/ESRD uncharacterized and also identifies renal failure within the differentiation-syndrome safety context.
What to reconcileDo not generate a renal dose from PK similarity. Assess renal deterioration with the complete oncology regimen and syndrome warnings.
1 source identities and dates
GlobalRPh RX List - REVUFORJGlobalRPh-hosted RX List | Source revision: Source revision date not established in selected retrieval.
Revumenib - REVUFORJ tablets; selected renal passages, not a complete prescribing monograph.
Read this stored source Source-specific interpretation; independent clinician adjudication pending. Added: v5.2.
scope and safety
Expected dialysis behavior is not a tested supplementation schedule
The source describes a PK range and an expected hemodialysis effect; it does not supply all dialysis-modality regimens.
What to reconcileRetain the distinction between observed PK and expectation. Do not infer a CRRT or peritoneal-dialysis dose.
1 source identities and dates
GlobalRPh RX List - REZZAYOGlobalRPh-hosted RX List | Source revision: Source revision date not established in selected retrieval.
Rezafungin - REZZAYO intravenous injection; selected renal passages, not a complete prescribing monograph.
Read this stored source Source-specific interpretation; independent clinician adjudication pending. Added: v5.2.
source scope difference
WAYRILZ: limited RX PK wording versus official severe-renal avoidance
The RX study boundary and the official categorical renal instruction are different types of evidence. A PK-only extraction can obscure a clinically important restriction.
What to reconcileRead official section 8.7 before use. Do not convert the lowest studied CrCl into a newly invented avoidance cutoff.
2 source identities and dates
GlobalRPh RX List - WAYRILZGlobalRPh-hosted RX List | Source revision: Source revision date not established in selected retrieval.
Rilzabrutinib - WAYRILZ tablets; selected renal passages, not a complete prescribing monograph.
Read this stored source WAYRILZ - official renal restrictionDailyMed / Genzyme Corporation | Source revision: Prescribing information revised August 2025.
WAYRILZ - official renal restriction; selected renal passages, not a complete prescribing monograph.
Read this stored source Source-specific interpretation; independent clinician adjudication pending. Added: v5.2.
scope and safety
Oral severe-renal titration must not be transferred to a long-acting injection
This source supplies an oral starting dose and titration limits, not a depot initiation or conversion algorithm.
What to reconcileConfirm oral formulation. A separate UZEDY record remains distinct.
1 source identities and dates
GlobalRPh RX List - RISPERDALGlobalRPh-hosted RX List | Source revision: Source revision date not established in selected retrieval.
Risperidone - RISPERDAL oral formulations; selected renal passages, not a complete prescribing monograph.
Read this stored source Source-specific interpretation; independent clinician adjudication pending. Added: v5.2.
formulation and sequence
Renal instructions require oral titration before this specific depot
UZEDY renal instructions use an oral-risperidone tolerability/titration step followed by a specific monthly subcutaneous regimen. They are not a generic conversion for all risperidone injections.
What to reconcileVerify product, route, titration and interaction history. Do not transfer this schedule to IM or every-two-month formulations.
1 source identities and dates
GlobalRPh RX List - UzedyGlobalRPh-hosted RX List | Source revision: Source revision date not established in selected retrieval.
UZEDY extended-release SUBCUTANEOUS injection after oral titration; not IM risperidone.
Read this stored source Source-specific interpretation; independent clinician adjudication pending. Added: v3.6.
scope and safety
Nonmonotonic oral PK cannot become a numerical renal-reduction table
The oral source reports differing directions of clearance change in its renal groups without resolving the reason.
What to reconcileDo not extrapolate a dose gradient or apply the oral study to a patch.
1 source identities and dates
GlobalRPh RX List - EXELON oralGlobalRPh-hosted RX List | Source revision: Source revision date not established in selected retrieval.
Rivastigmine - EXELON oral capsules; selected renal passages, not a complete prescribing monograph.
Read this stored source Source-specific interpretation; independent clinician adjudication pending. Added: v5.2.
scope and safety
Patch population analysis is not an oral renal-dose protocol
The patch source describes a population analysis rather than a dedicated renal study or numerical renal algorithm.
What to reconcileKeep the transdermal and oral sources separated and retain uncertainty.
1 source identities and dates
GlobalRPh RX List - EXELON PATCHGlobalRPh-hosted RX List | Source revision: Source revision date not established in selected retrieval.
Rivastigmine - EXELON transdermal patch; selected renal passages, not a complete prescribing monograph.
Read this stored source Source-specific interpretation; independent clinician adjudication pending. Added: v5.2.
scope and safety
No renal adjustment does not remove hypocalcemia or cardiovascular safeguards
The two sources agree on no renal adjustment while retaining high-risk calcium monitoring. Nonrenal eligibility remains separate.
What to reconcileCheck calcium status and complete product eligibility. Do not import PROLIA monitoring intervals or invent a smaller renal dose.
2 source identities and dates
GlobalRPh RX List - EVENITYGlobalRPh-hosted RX List | Source revision: Source revision date not established in selected retrieval.
Romosozumab - EVENITY subcutaneous injection; selected renal passages, not a complete prescribing monograph.
Read this stored source EVENITY - official renal safety checkDailyMed / Amgen Inc. | Source revision: Prescribing information revised January 2026.
EVENITY - official renal safety check; selected renal passages, not a complete prescribing monograph.
Read this stored source Source-specific interpretation; independent clinician adjudication pending. Added: v5.2.
scope and safety
Avoidance below the source threshold is not a dose-reduction opportunity
The selected source attaches renal avoidance and creatinine monitoring to the no-adjustment group.
What to reconcilePreserve the source units; do not silently add BSA indexing or create a lower-function regimen.
1 source identities and dates
GlobalRPh RX List - BESREMiGlobalRPh-hosted RX List | Source revision: Source revision date not established in selected retrieval.
Ropeginterferon alfa-2b - BESREMi subcutaneous injection; selected renal passages, not a complete prescribing monograph.
Read this stored source Source-specific interpretation; independent clinician adjudication pending. Added: v5.2.
scope and safety
ER Parkinson regimen is not the IR RLS schedule
The official ER source has a once-daily dialysis starting regimen. Its maximum does not make IR and ER starting doses or indications interchangeable.
What to reconcileConfirm exact release formulation and indication. The failed REQUIP XL mirror has not been recovered by adding an official generic label.
1 source identities and dates
Ropinirole - extended-release tabletsDailyMed / Elite Laboratories, Inc. | Source revision: Prescribing information revised November 2025.
Ropinirole - extended-release tablets; selected renal passages, not a complete prescribing monograph.
Read this stored source Source-specific interpretation; independent clinician adjudication pending. Added: v5.2.
professional treatment selection
Ropinirole: indication-specific renal instructions versus routine RLS treatment selection
IR renal instructions differ between Parkinson disease and RLS. The AASM abstract conditionally discourages standard ropinirole use for adult RLS; it addresses treatment selection, not a competing renal dose.
What to reconcileConfirm indication and IR formulation before using a schedule. Review patient-specific reasons to select this treatment; the professional source is an abstract, not a full guideline review.
3 source identities and dates
GlobalRPh RX List - REQUIPGlobalRPh-hosted RX List | Source revision: Source revision date not established in selected retrieval.
Ropinirole - immediate-release tablets; selected renal passages, not a complete prescribing monograph.
Read this stored source Ropinirole IR - official indication and dialysis checkDailyMed / Direct_Rx | Source revision: PI revision date not established in this selected HTML retrieval.
Ropinirole IR - official indication and dialysis check; selected renal passages, not a complete prescribing monograph.
Read this stored source AASM - RLS treatment-selection qualificationAmerican Academy of Sleep Medicine / SLEEP guideline abstract | Source revision: SLEEP 2025, volume 48 supplement 1, page A393.
Published conference abstract summarizing the AASM guideline. The full JCSM guideline was not independently retrieved/read in this release; no full-guideline review is claimed.
Read this stored source Source-specific interpretation; independent clinician adjudication pending. Added: v5.2.
scope and safety
Preserve indexed creatinine-clearance units and the nondialysis qualification
The RX renal instruction is explicitly indexed and excludes hemodialysis from the stated severe-renal regimen.
What to reconcileDo not silently relabel the metric or extend the nondialysis regimen to dialysis. Review other myopathy and interaction risks.
1 source identities and dates
GlobalRPh RX List - CRESTORGlobalRPh-hosted RX List | Source revision: Source revision date not established in selected retrieval.
Rosuvastatin - CRESTOR tablets; selected renal passages, not a complete prescribing monograph.
Read this stored source Source-specific interpretation; independent clinician adjudication pending. Added: v5.2.
scope and safety
Dialysis exposure changes do not specify a supplemental dose
Severe nondialysis PK and dialysis-related exposure changes are separate findings. The source says to consider an adjustment without quantifying it.
What to reconcileDo not convert an exposure percentage into dose arithmetic. Seek a supported patient- and modality-specific plan.
1 source identities and dates
GlobalRPh RX List - BANZELGlobalRPh-hosted RX List | Source revision: Source revision date not established in selected retrieval.
Rufinamide - BANZEL oral tablets and suspension; selected renal passages, not a complete prescribing monograph.
Read this stored source Source-specific interpretation; independent clinician adjudication pending. Added: v5.2.
indication and blood count
CrCl alone does not select the JAKAFI starting regimen
The renal starting-dose table changes by indication and, for myelofibrosis, platelet count. The dialysis rows also use indication-specific post-dialysis schedules.
What to reconcileEstablish indication and platelet category before reading a dose. This selected table is not the full cytopenia, interaction or toxicity-management algorithm.
1 source identities and dates
GlobalRPh RX List - JAKAFIGlobalRPh-hosted RX List | Source revision: Source revision date not established in selected retrieval.
Oral ruxolitinib: adult myelofibrosis/polycythemia vera and indication-specific GVHD starting regimens; confirm the labeled age and hematologic eligibility. Not topical ruxolitinib.
Read this stored source Source-specific interpretation; independent clinician adjudication pending. Added: v3.6.